Aflibercept monotherapy or bevacizumab first for diabetic macular edema

Purpose: Clinical outcome and switch patterns with bevacizumab first treatment strategy for patients with newly diagnosed neovascular age-related macular degeneration (nAMD). Methods: Retrospective observational study of the number of intravitreal injections of bevacizumab and treatment switch in pa...

Full description

Bibliographic Details
Published in:	Indian Journal of Ophthalmology
Main Authors:	Avner Hostovsky, Iris Moroz, Gabriel Katz
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-01-01
Subjects:	aflibercept bevacizumab intravitreal injection ranibizumab switch
Online Access:	http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=14;spage=260;epage=264;aulast=Hostovsky

Similar Items

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021-07-01)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
by: Sumit Randhir Singh, et al.
Published: (2019-01-01)

Management of Macular Edema Secondary to Branch Retinal Vein Occlusion in an Eye with Prior Vitrectomy and Lensectomy
by: Pankaj Malhotra, et al.
Published: (2014-10-01)

Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes
by: Sebile Comcali, et al.
Published: (2025-05-01)

Effectiveness of aflibercept in treating bevacizumab resistant macular edema
by: Hussain Khudair Yassin
Published: (2024-12-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina
by: Svjetlana Terzić, et al.
Published: (2015-08-01)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
by: Jing Chen, et al.
Published: (2023-10-01)

Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments
by: Anna-Kaisa Rimpelä, et al.
Published: (2018-12-01)

Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens
by: Yoo-Ri Chung, et al.
Published: (2023-03-01)

Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2021-01-01)

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
by: Ali Salimi, et al.
Published: (2021-01-01)

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
by: S. V. Nedogoda, et al.
Published: (2020-03-01)

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
by: Bhagya Weerasinghe, et al.
Published: (2021-01-01)

Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review
by: Joel Uzzan, et al.
Published: (2024-07-01)

Comparison of Corneal Endothelial Changes After a Single-Dose Injection of Bevacizumab or Ranibizumab
by: Fatih Horozoğlu, et al.
Published: (2013-12-01)

An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data
by: Dominic Muston, et al.
Published: (2018-12-01)

Transient Vision Loss Associated with Prefilled Aflibercept Syringes
by: Daniel J. Lee, MD, et al.
Published: (2022-06-01)

Effects of Intravitreal Injection of Ranibizumab and Aflibercept on Corneal Endothelium and Central Corneal Thickness
by: Mehmet Coskun
Published: (2018-08-01)

A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
by: Mahmut Kaya, et al.
Published: (2023-02-01)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
by: Dorota Luksa, et al.
Published: (2021-11-01)

Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience
by: Osman Parca, et al.
Published: (2024-03-01)

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration
by: Simon D Archambault, et al.
Published: (2024-01-01)

Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab
by: Dimitrios Maris, et al.
Published: (2024-06-01)

Treatment Effects of Switching to Faricimab in Eyes with Diabetic Macular Edema Refractory to Aflibercept
by: Tomoaki Tatsumi, et al.
Published: (2024-04-01)

Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
by: J. M. Ruiz-Moreno, et al.
Published: (2020-09-01)

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
by: Eloi Debourdeau, et al.
Published: (2023-07-01)

Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs
by: Małgorzata Figurska, et al.
Published: (2021-12-01)

Comparison of the effects of 3 different anti-VEGF drugs on cornea thickness, lens thickness and anterior chamber depth
by: Mehmet Tahir Eski, et al.
Published: (2023-03-01)

Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema
by: Hossam El Deen Khalil, et al.
Published: (2022-07-01)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
by: Hiromi Ohara, et al.
Published: (2023-06-01)

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study
by: Abdullah Özkaya, et al.
Published: (2017-05-01)

Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema:a systemic review and Meta-analysis
by: Xiang-Dong Liu, et al.
Published: (2014-12-01)

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01)

Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting
by: Munayco-Guillén F, et al.
Published: (2023-04-01)

Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients
by: Akiko Kin, et al.
Published: (2024-07-01)

Deformation of Aflibercept and Ranibizumab Syringes Causes Variation in Intravitreal Injection Volume and Risks Retinal Tear Formation
by: Joseph J. Raevis, MD, et al.
Published: (2022-12-01)

Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe
by: John-Michael Guest, et al.
Published: (2022-04-01)

Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
by: Yawara Kikuchi, et al.
Published: (2022-10-01)